Nivolumab Websites
Healthcare Professional Site | OPDIVO® (nivolumab)
Learn about OPDIVO® for patients with Previously Treated Metastatic Squamous and Non-Squamous Non-Small Cell Lung Cancer (NSCLC). Please see Indication and Important Safety Information.
Not Applicable
$
8.95
OPDIVO® (nivolumab) | Patient Gateway
OPDIVO® (nivolumab) is a prescription medication. Read about its indications, side effects, and more.
Not Applicable
$
8.95
OPDIVO® (nivolumab) | Metastatic NSCLC | Healthcare Professionals Hom
OPDIVO® (nivolumab), for patients with previously treated metastatic non-small cell lung cancer (NSCLC). See Indication and Important Safety Information.
Not Applicable
$
8.95
OPDIVO® (nivolimab) | Relapsed or Progressed cHL after auto-HSCT
OPDIVO® (nivolumab), for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after autologous HSCT and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT.
Not Applicable
$
8.95
